Stefanie Schmidt

Stefanie Schmidt

Auto-generated profile, based on publicly available information

Stefanie Schmidt

Department of Anaesthesiology, Universitätsklinikum Erlangen, Friedrich–Alexander-Universität Erlangen–Nürnberg (FAU), Germany

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2022 in International Journal of Analytical Chemistry
Verified
Journal Article
Open access
PDF file
AWAndreas Wehrfritz
Andreas Wehrfritz
SSStefanie Schmidt
Stefanie Schmidt
HIHarald Ihmsen
Harald Ihmsen
JSJürgen Schüttler
Jürgen Schüttler
CJChristian Jeleazcov
Christian Jeleazcov
The long-term stability of drugs under normal laboratory storage conditions (−20°C) for years is important for research purposes, clinical re-evaluation, and also for forensic toxicology. To evaluate the stability of the analgesic opioid hydromorphone, 44 human frozen plasma samples of a former clinical trial were reanalyzed after at least three years. Blood samples were disposed using solid-phase extraction with an additional substitution of stable isotope labelled hydromorphone as an internal standard. Hydromorphone concentrations were determined by ultra-performance liquid chromatography (UPLC) with gradient elution, followed by tandem mass spectrometry with electrospray ionization. Calibration curves demonstrated linearity of the assay in the concentration range of 0.3–20 ng/mL hydromorphone. The limit of detection of the hydromorphone plasma concentration was 0.001 ng/mL, and the lower limit of quantification was 0.3 ng/mL. Intra- and interassay errors did not exceed 16%. The percentage deviation of the measured hydromorphone plasma concentrations between the reanalysis and the first analysis was −1.07% ± 14.8% (mean ± SD). These results demonstrate that hydromorphone concentration in human plasma was stable when the samples were frozen at −20°C over three years. This finding is of value for re-evaluations or delayed analyses for research purposes and in pharmacokinetic studies, such as in forensic medicine.

6 December 2022 in Journal of Chromatographic Science
Verified
Journal Article
Closed access
SSStefanie Schmidt
Stefanie Schmidt
LKLjubica Krajinovic
Ljubica Krajinovic
CMChristian Mertens
Christian Mertens
LSLisa Schramm
Lisa Schramm
JSJürgen Schüttler
Jürgen Schüttler
JFJörg Fechner
Jörg Fechner
A new assay was developed to measure the concentration of remimazolam besylate (CNS7056B) and its major carboxylic acid metabolite (CNS7054X) in human plasma. For this new assay method, midazolam-d4 maleate was used as an internal standard. After setting up a previously described assay method, using CNS7056-d4 and CNS7054-d4 as internal standards, analytical results of both methods were compared. For the new analytical method, ultra-high-performance liquid chromatography (UHPLC) with tandem mass spectrometry was applied. A purification method, using solid phase extraction, was developed and validated. The chromatographic separation of the analytes was achieved with a mobile phase gradient using a Water Acquity™ UHPLC-System. The Kinetex™ biphenyl 50 × 2.1 mm UHPLC column was used with a particle diameter of 1.7 μm (Phenomenex, Germany). A measuring range of 0.6–2,000 ng/mL for CNS7056B and of 6–20,000 ng/mL for CNS7054X could be achieved with this new assay. The lower limit of quantification was 0.6 ng/mL for CNS7056B and 6 ng/mL for CNS7054X. The assay was validated according to US Food and Drug Administration guidelines. The new method showed an accuracy of 96.9–110.4% and a precision of 2.1–6.7% for both analytes.

17 October 2024 in Journal of Analytical Toxicology
Verified
Journal Article
Closed access
PDF file
AWAndreas Wehrfritz
Andreas Wehrfritz
SSStefanie Schmidt
Stefanie Schmidt
HIHarald Ihmsen
Harald Ihmsen
JSJürgen Schüttler
Jürgen Schüttler
CJChristian Jeleazcov
Christian Jeleazcov
The long-term stability of drug concentrations in human plasma samples, when stored under normal laboratory conditions over several years, is important for research purposes and clinical re-evaluation, and forensic toxicology. Fifty human plasma samples from a former clinical trial were re-analyzed after storage at −20°C for 11 years. Plasma samples were extracted using solid-phase extraction. Isotope labeled sufentanil-d5 was used as internal standard. Sufentanil plasma concentrations were determined by ultra-performance liquid chromatography with gradient elution, followed by tandem mass spectrometry with electrospray ionization. The linear dynamic range was 25–2500 pg/mL, the limit of detection was 10 pg/mL, and the lower limit of quantification was 25 pg/mL. Intra- and inter-assay error did not exceed 6%. The deviation of the measured sufentanil plasma concentrations between the re-analysis and the first analysis was −63 ± 14% (mean ± SD). Therefore, sufentanil concentrations in human plasma were not stable in samples frozen at −20°C over 11 years.

1 January 2026 in International Journal of Analytical Chemistry
Verified
Journal Article
Open access
SSStefanie Schmidt
Stefanie Schmidt
HIHarald Ihmsen
Harald Ihmsen
TGTobias Golditz
Tobias Golditz
JSJürgen Schüttler
Jürgen Schüttler
AWAndreas Wehrfritz
Andreas Wehrfritz
Dipyrone (metamizole) is widely used as a nonopioid analgesic in perioperative and intensive care settings; however, its administration may be associated with severe adverse effects. In this study, we describe an analytical assay for the quantification of the active metabolites 4‐methylaminoantipyrine (4‐MAA) and 4‐aminoantipyrine (4‐AA) in human plasma using ultra‐high‐performance liquid chromatography coupled with tandem mass spectrometry (UPLC–MS/MS). In addition, the protein‐unbound fractions of both metabolites were determined by ultrafiltration. Chromatographic separation was performed on a UPLC system using gradient elution, followed by MS/MS detection with an electrospray ionization source. The limits of detection for both metabolites were 100 ng/mL. Across the investigated concentration range (100–10,000 ng/mL), the relative error (%RE) ranged from −6.3% to +3.5%. Intra‐day and inter‐assay variability were below 10%. Method validation was conducted in accordance with the 2018 FDA Bioanalytical Method Validation Guidance, and all evaluated parameters met the required criteria for analytical accuracy and precision. The developed assay is suitable for monitoring dipyrone metabolites and may support the prevention of potential overdosing during prolonged analgesic therapy or in intensive care settings.

1 January 2025 in International Journal of Analytical Chemistry
Verified
Journal Article
Open access
SSStefanie Schmidt
Stefanie Schmidt
HIHarald Ihmsen
Harald Ihmsen
TMTino Münster
Tino Münster
JSJürgen Schüttler
Jürgen Schüttler
CJChristian Jeleazcov
Christian Jeleazcov
AWAndreas Wehrfritz
Andreas Wehrfritz
The intravenous anesthetic propofol is frequently used for the induction and maintenance of general anesthesia. Propofol has, however, a potential for abuse, and it has been involved in suicide deaths particularly among medical personnel. The long‐term stability of propofol concentrations in human plasma samples when stored under normal laboratory conditions over several years might be important for forensic toxicology. The present study investigated the long‐term stability of propofol after storage at −20°C for eight years. For this purpose, 67 plasma samples from five patients, who had undergone a former clinical trial, were re‐analyzed. Plasma samples were extracted using protein precipitation. Propofol plasma concentrations were determined by ultra‐performance liquid chromatography (UPLC) with gradient elution, followed by tandem mass spectrometry with electrospray ionization. Deuterium‐labeled propofol was used as an internal standard. The assay was linear in the range of 50–10,000 ng/mL with a limit of detection of 0.5 ng/mL and a lower limit of quantification of 50 ng/mL, respectively. Accuracy and precision were high with intra‐ and interassay errors within ±5%. The median relative deviation between the measurements in 2023 and 2015 was −7.0% (interquartile range: −19.7% and 5.3%). Therefore, propofol concentrations in human plasma can be considered relatively stable in samples frozen at −20°C over eight years, and plasma samples stored under these conditions might be used for forensic purposes. Trial Registration: ClinicalTrials.gov identifier: NCT02199067

1 January 2026 in Sage Open Medical Case Reports
Verified
Journal Article
Open access
AWAndreas Wehrfritz
Andreas Wehrfritz
SSStefanie Schmidt
Stefanie Schmidt
HIHarald Ihmsen
Harald Ihmsen
SFSteffen Fiedler
Steffen Fiedler
FVFelix Volleth
Felix Volleth
ICIxchel Castellanos
Ixchel Castellanos
Dipyrone (metamizole) is a widely used non-opioid analgesic. Its use is restricted due to the risk of side effects such as liver toxicity. We report the case of a patient who accidentally received an oral dose of 12.5 g (132 mg/kg) dipyrone. The patient was monitored for the next 62 days and remained asymptomatic, showing no signs of gastrointestinal, hepatic, or other toxicity. Dipyrone was not detectable in the plasma, while the plasma concentrations of its active metabolites 4-methylaminoantipyrine and 4-aminoantipyrine were elevated. The pharmacokinetics were best described by nonlinear one-compartment models with Michaelis–Menten elimination. The terminal half-life of both metabolites was 2.9 h. These results demonstrate the rapid absorption of dipyrone and the extremely short window for effective gastric decontamination. Due to its specific pharmacokinetic profile, the high systemic exposure to active dipyrone metabolites did not result in acute organ toxicity in this case. Therefore, intensive medical monitoring may not always be mandatory after dipyrone overdose in otherwise clinically stable patients, although agranulocytosis remains as idiosyncratic long-term risk.